Human Active MMP-9 Fluorokine E Kit

Contains Mercury, Dispose According to Local, State or Federal Laws
Catalog # Availability Size / Price Qty
Product Details
Citations (18)
Reviews (2)

Human Active MMP-9 Fluorokine E Kit Summary


Shipping Conditions
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Store the unopened product at 2 - 8 °C. Do not use past expiration date.

Product Datasheets

You must select a language.


Background: MMP-9

The matrix metalloproteinases (MMPs) consist of 24 known human zinc proteases with essential roles in breaking down components of the extracellular matrix (ECM). Additional MMP substrates include cytokines, chemokines, growth factors and binding proteins, cell/cell adhesion molecules, and other proteinases. With a few exceptions, MMPs share common structural motifs including a pro-peptide domain, a catalytic domain, a hinge region, and a hemopexin-like domain. Synthesized as pro-enzymes, most MMPs are secreted before conversion to their active form. MMP activities are modulated on several levels including transcription, pro-enzyme activation, or by their endogenous inhibitors, tissue inhibitors of metalloproteinases (TIMPs). A subset of MMPs are associated with membranes and designated as membrane-type metalloproteinases (MT-MMP).

Long Name
Matrix Metalloproteinase 9
Entrez Gene IDs
4318 (Human); 17395 (Mouse); 81687 (Rat); 102117693 (Cynomolgus Monkey)
Alternate Names
92 kDa gelatinase; 92 kDa type IV collagenase; CLG4B; EC 3.4.24; EC; Gelatinase B; GELB; macrophage gelatinase; MANDP2; matrix metallopeptidase 9; matrix metalloproteinase 9; matrix metalloproteinase-9; MMP9; MMP-9; type V collagenase
⚠ WARNING: This product can expose you to chemicals including mercury, which is known to the State of California to cause reproductive toxicity with developmental effects. For more information, go to

Citations for Human Active MMP-9 Fluorokine E Kit

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

18 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. Enhancement of Farnesoid X Receptor Inhibits Migration, Adhesion and Angiogenesis through Proteasome Degradation and VEGF Reduction in Bladder Cancers
    Authors: CR Lai, HH Wang, HH Chang, YL Tsai, WC Tsai, CR Lee, CY Changchien, YC Cheng, ST Wu, Y Chen
    International Journal of Molecular Sciences, 2022-05-09;23(9):.  2022-05-09
  2. The psychoactive drug of abuse mephedrone differentially disrupts blood-brain barrier properties
    Authors: TP Buzhdygan, CR Rodrigues, HM McGary, JA Khan, AM Andrews, SM Rawls, SH Ramirez
    Journal of Neuroinflammation, 2021-03-01;18(1):63.  2021-03-01
  3. Enhanced closed eye neutrophil degranulation in dry eye disease
    Authors: CK Postnikoff, K Held, V Viswanath, KK Nichols
    Ocul Surf, 2020-09-02;18(4):841-851.  2020-09-02
  4. Cyclooxygenase-2 in tumor-associated macrophages promotes metastatic potential of breast cancer cells through Akt pathway
    Int. J. Biol. Sci, 2016-11-26;12(12):1533-1543.  2016-11-26
  5. The differential effects of azithromycin on the airway epithelium in�vitro and in�vivo
    Physiol Rep, 2016-09-01;4(18):.  2016-09-01
  6. Interplay between Matrix Metalloproteinase-9, Matrix Metalloproteinase-2, and Interleukins in Multiple Sclerosis Patients
    Dis Markers, 2016-07-31;2016(0):3672353.  2016-07-31
  7. The TNF Family Molecules LIGHT and Lymphotoxin alphabeta Induce a Distinct Steroid-Resistant Inflammatory Phenotype in Human Lung Epithelial Cells.
    Authors: da Silva Antunes R, Madge L, Soroosh P, Tocker J, Croft M
    J Immunol, 2015-07-24;195(5):2429-41.  2015-07-24
  8. Regulation of MMP-9 by a WIN-binding site in the monocyte-macrophage system independent from cannabinoid receptors.
    Authors: Tauber, Svantje, Paulsen, Katrin, Wolf, Susanne, Synwoldt, Peggy, Pahl, Andreas, Schneider-Stock, Regine, Ullrich, Oliver
    PLoS ONE, 2012-11-06;7(11):e48272.  2012-11-06
  9. Host gene-encoded severe lung TB: from genes to the potential pathways.
    Authors: Ganachari, M, Guio, H, Zhao, N, Flores-Villanueva, P O
    Genes Immun, 2012-09-20;13(8):605-20.  2012-09-20
  10. Early Elevation of Matrix Metalloproteinase-8 and -9 in Pediatric ARDS Is Associated with an Increased Risk of Prolonged Mechanical Ventilation.
    Authors: Kong MY, Li Y, Oster R, Gaggar A, Clancy JP
    PLoS ONE, 2011-08-03;6(8):e22596.  2011-08-03
  11. Primary human acute myelogenous leukemia cells release matrix metalloproteases and their inhibitors: release profile and pharmacological modulation.
    Authors: Reikvam H, Hatfield KJ, Oyan AM, Kalland KH, Kittang AO, Bruserud O
    Eur. J. Haematol., 2009-11-17;84(3):239-51.  2009-11-17
  12. Serum matrix metalloproteinases in adult CF patients: Relation to pulmonary exacerbation.
    Authors: Roderfeld M, Rath T, Schulz R, Seeger W, Tschuschner A, Graf J, Roeb E
    J. Cyst. Fibros., 2009-07-14;8(5):338-47.  2009-07-14
  13. Salbutamol up-regulates matrix metalloproteinase-9 in the alveolar space in the acute respiratory distress syndrome.
    Authors: O'Kane CM, McKeown SW, Perkins GD, Bassford CR, Gao F, Thickett DR, McAuley DF
    Crit. Care Med., 2009-07-01;37(7):2242-9.  2009-07-01
  14. The presence of a matrix-derived neutrophil chemoattractant in bronchiolitis obliterans syndrome after lung transplantation.
    Authors: Hardison MT, Galin FS, Calderon CE, Djekic UV, Parker SB, Wille KM, Jackson PL, Oster RA, Young KR, Blalock JE, Gaggar A
    J. Immunol., 2009-04-01;182(7):4423-31.  2009-04-01
  15. Matrix metalloproteinase activity in pediatric acute lung injury.
    Authors: Kong MY, Gaggar A, Li Y
    Int J Med Sci, 2008-12-16;6(1):9-17.  2008-12-16
  16. Differential proteolytic enzyme activity in eosinophilic and neutrophilic asthma.
    Authors: Simpson JL, Scott RJ, Boyle MJ, Gibson PG
    Am. J. Respir. Crit. Care Med., 2005-05-18;172(5):559-65.  2005-05-18
  17. Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease.
    Authors: Schieffer B, Bunte C, Witte J, Hoeper K, Boger RH, Schwedhelm E, Drexler H
    J. Am. Coll. Cardiol., 2004-07-21;44(2):362-8.  2004-07-21
  18. Implications for matrix metalloproteinases as modulators of pediatric lung disease.
    Authors: Winkler MK, Foldes JK, Bunn RC, Fowlkes JL
    Am. J. Physiol. Lung Cell Mol. Physiol., 2002-11-27;284(4):L557-65.  2002-11-27


  1. Does the Human Active MMP-9 Fluorokine E Kit detect active or pro-MMP-9?

    • Without using APMA before substrate addition, the kit measures the levels of endogenous active MMP-9. With using APMA before substrate addition, the kit measures the levels of endogenous active MMP-9 and levels of the MMP-9 that can be activated by APMA, which reflects the sum of active MMP-9 and pro-MMP-9.

View all Activity Assay FAQs

Reviews for Human Active MMP-9 Fluorokine E Kit

Average Rating: 5 (Based on 2 Reviews)

5 Star
4 Star
3 Star
2 Star
1 Star

Have you used Human Active MMP-9 Fluorokine E Kit?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:

Human Active MMP-9 Fluorokine E Kit
By Anonymous on 01/20/2021

Easy to use and gives reliable results.

Human Active MMP-9 Fluorokine E Kit
By Leslie Priddy on 04/04/2018